Press Releases - Supernus Pharmaceuticals

Date	Title
May 9, 2022	Supernus Announces First Quarter 2022 Financial Results	PDF Version
May 2, 2022	Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022	PDF Version
April 29, 2022	Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults	PDF Version
April 13, 2022	Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results	PDF Version
April 4, 2022	Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance	PDF Version
March 17, 2022	Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance	PDF Version
March 2, 2022	Supernus to Participate in Annual Cowen Health Care Conference	PDF Version
February 28, 2022	Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results	PDF Version
February 22, 2022	Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022	PDF Version
February 22, 2022	Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA	PDF Version